For reconstitution, the patient twists the Q Cap(TM) onto the syringe, pushes the tip through the diluent vial's rubber stopper, and pulls back on the plunger to remove the diluent. Next, the patient places the Q Cap(TM) on the vial containing the Bravelle(R) or Repronex(R) powder, pushes the tip into the rubber stopper, then slowly injects the diluent into the vial and swirls the diluent and medication until the medication is dissolved. The solution can be used to dissolve up to six vials in one syringe.
Repronex(R) is the only human menopausal gonadotropin (hMG) on the market and is approved for both subcutaneous and intramuscular administration. Bravelle(R) and Repronex(R), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.
PHILADELPHIA, Oct. 18 /PRNewswire/ Ferring Pharmaceuticals introduced today the Q Cap(TM), the first device enabling needle free reconstitution (process of dissolving medication in diluent) of fertility treatments. It is for exclusive use with the Company's human derived fertility treatments and will be packaged with Bravelle(R) (urofollitropin for injection, purified). The device allows user friendly reconstitution of medication(s) in a single vial, in single or mixed protocols, simplifying preparation for injection, and eliminating product waste and accidental needle sticks. The Q Cap(TM) was previewed at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Philadelphia, October 16 20, 2004."In a recent survey by the International Council on Infertility Information Dissemination (INCIID), 77% of the 537 in vitro fertilization (IVF) polled patients reported reconstitution as the most stressful part of IVF therapy," said William Garbarini, director of marketing, Ferring Pharmaceuticals. "Part of that stress was specifically attributed to the use of needles. Since the Q Cap(TM) is needle free, it eliminates patients' anxiety associated with needle use during this process and increases comfort levels, making patients more confident in their self treatment while ensuring that the full prescribed medication dose is administered from the vial."
2 Introduces BravelleR With First Needle Free Reconstitution Devi
How Q Cap(TM) Works
KV Pharmaceutical Company (KVA) Licensing Partner Ferring, Inc. Receives Approval To Market Gynazole 1(R) In CanadaNPS Pharmaceuticals (NPSP) Reports Inconclusive Adidas Cap
The Q Cap(TM) can be used to reconstitute medication(s) in one syringe regardless of protocol and allows the patient to administer only one injection per day. If more than one medication is required, the patient simply repeats the process with the additional vial(s) of medication(s) before attaching the injection needle to the vial. This improved reconstitution process reduces time required to educate patients since it mirrors the reconstitution process with the standard needle and syringe technique, eliminates accidental needle sticks New Era Florida Panthers and eliminates product waste.
The Q Cap(TM) provides fast and easy reconstitution that is consistent with the traditional needle and syringe injection method that patients have become accustomed to and may need to use with other medications prescribed during their treatment cycle. It allows patients to easily withdraw the full contents of each vial needle free. It does not interfere with the patient's ability to withdrawal her full dose without wasting product.
Results Of Acute Migraine Study.
"The Q Cap(TM) is a new feature designed to make self treatment with Bravelle(R) easier and less stressful for patients," said Dr. Richard T. Scott, Jr., Director and Managing Partner of Reproductive Medicine Associates of New Jersey. "Another benefit of the Q Cap(TM) is that it requires only one injection in mixed protocols, whereas other devices require at least two. By using the Q Cap(TM), different ratios of Bravelle(R) and Repronex(R) can be delivered in one syringe to meet individual patient needs."About Bravelle(R) and Repronex(R)
follicular development during ART cycles in patients who have previously received pituitary suppression.
Degarelix, A New GnRH Blocker From Ferring Pharmaceuticals, Inc., Shows Rapid Onset And Sustained Activity In A Phase II Clinical Study In Men With Prostate CancerAlcon (ACL) Announces Anecortave Acetate Clinical Results; Did Not Meet The Primary Non Inferiority Endpoint
Bravelle(R), a highly purified human derived follicle stimulating hormone New Era Nfl Hats 2016
(hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle(R), administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle(R), administered SC in conjunction with hCG, is also indicated for multiple New Era Snapbacks Nba
The device can also be used with Ferring's Repronex(R) (menotropins for injection, USP) fertility treatment.
Nike Caps Tumblr
New Era Cap New York Yankees
Ny Yankees Cap Blue
New Era La Dodgers Hat
New Era Caps Boston Red Sox
Jordan Hats Uk
High Quality Louis Vuitton Belt
Versace Belts Red
Hermes Belt Red And Gold
Jordan Hats White
New Era La Blue
Gucci Belt Monogram
New Era Hat Collection
Gucci Belts Gray
Jordan Caps For Girls